Abbott Laboratories ABT has been gaining investor confidence on continued positive results. The company's share price has outperformed its  industry over the past year. The stock has gained 9.1% against its industry's 6.3% decline and the S&P 500's 6.5% fall in the said period.
This leading developer, manufacturer and seller of a diversified line of health care products has a market cap of $124.96 billion. The company has an expected earnings growth rate of 11.8% over the next three-five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
Strong EPD Business
Abbott's EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America.
The company recently noted that banking on successful execution of the Branded Generic operating model, EPD is well positioned for sustained above-market growth in many of these growing pharmaceutical markets. Sales were strong in the las t report ed quarter, led by double-digit growth in both India and China.
